Opportunity ID: 359060
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PCRPCCA |
| Funding Opportunity Title: | DoD Prostate Cancer, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 12 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | May 20, 2025 |
| Last Updated Date: | May 27, 2025 |
| Original Closing Date for Applications: | Aug 29, 2025 |
| Current Closing Date for Applications: | Aug 29, 2025 |
| Archive Date: | Sep 28, 2025 |
| Estimated Total Program Funding: | $32,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease. Distinctive Features: · This award mechanism does not support the development of clinical protocols. · Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site. · Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The program announcement (PA) and synopsis have been updated to reflect changes to the Expected Number of Awards and Estimated Total Program Funding amount. The direct cost cap has been changed to a total cost cap in the PA. The PA has also been updated on page 4, 13 and 14 to incorporate these changes. Additionally, a link on page 33 of the PA has been updated. | May 27, 2025 | |
| updating the Expected Number of Awards and Estimated Total Program Funding amounts. | May 20, 2025 | |
| May 20, 2025 |
DISPLAYING: Synopsis 3
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PCRPCCA |
| Funding Opportunity Title: | DoD Prostate Cancer, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 12 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 3 |
| Posted Date: | May 20, 2025 |
| Last Updated Date: | May 27, 2025 |
| Original Closing Date for Applications: | Aug 29, 2025 |
| Current Closing Date for Applications: | Aug 29, 2025 |
| Archive Date: | Sep 28, 2025 |
| Estimated Total Program Funding: | $32,500,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease. Distinctive Features: · This award mechanism does not support the development of clinical protocols. · Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site. · Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PCRPCCA |
| Funding Opportunity Title: | DoD Prostate Cancer, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 12 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 20, 2025 |
| Last Updated Date: | May 20, 2025 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 29, 2025 |
| Archive Date: | Sep 28, 2025 |
| Estimated Total Program Funding: | $36,800,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease. Distinctive Features: · This award mechanism does not support the development of clinical protocols. · Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site. · Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT942525PCRPCCA |
| Funding Opportunity Title: | DoD Prostate Cancer, Clinical Consortium Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 1 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 20, 2025 |
| Last Updated Date: | May 20, 2025 |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Aug 29, 2025 |
| Archive Date: | Sep 28, 2025 |
| Estimated Total Program Funding: | $12,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
Summary: The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease. Distinctive Features: · This award mechanism does not support the development of clinical protocols. · Coordinating Center: This award mechanism supports one coordinating center, which will be responsible for development and maintenance of the consortium organizational structure, and also function as a Clinical Research Site. · Clinical Research Sites: This award mechanism supports multiple clinical research sites, which will be responsible for clinical trial introduction and selection, patient accrual for consortium studies, data collection and timely submissions, meeting attendance, and adherence to the consortium’s operating procedures. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Related Documents
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00290840 | May 20, 2025 | Aug 29, 2025 | View |
Package 1
Mandatory forms
Optional forms
Share This Post, Choose Your Platform!
About the Author: osnqt
